Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

Chief, Digestive Disease Institute, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, New York; Associate Professor of Medicine, New York University School of Medicine, New ...

People who inject drugs have historically struggled to get treatment for the virus. Here’s how one physician has helped fight the stigma. When Lynn Taylor, MD, was in medical school, she studied under ...

BOSTON (AP) Quick treatment after infection can almost always cure hepatitis C, a condition that causes between 8,000 and 10,000 deaths in the United States each year, according to a study released ...

NEW YORK (Reuters) - A hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal trial of previously untreated patients, the company said on ...

This morning Gilead ($GILD) announced that it has successfully wrapped up positive top-line data from its fourth and last Phase III study for sofosbuvir, putting the ...